Study to Evaluate GR1801's Efficacy and Safety

Clinical trial NCT05846568 · COMPLETED

Trial details

NCT number: NCT05846568
Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Rabies Post-exposure Prophylaxis

Start date: 2022-10-21
Primary completion: 2023-09-06
Enrollment: 1200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.